Sarah Pringle

While Varma is supportive of a shutdown, he said the medical damage to patients with other diseases is going to become insurmountable.

PE firms move slowly into offense mode amid the coronavirus crisis and Thoma Bravo shelves its sale of Imprivata.

Across the private equity industry, the impacts of the pandemic-spurred economic downturn are being felt in dealmaking, which has slowed or paused fundraising processes while LPs work to understand the status of their portfolios.

While many traditional PE shops are busy assessing the potential impacts of covid-19 on their portfolios, a few are turning to their companies to develop vaccines and tests to curb the spread of coronavirus.

Imprivata, which helps healthcare providers protect patient information, was anticipated to command upwards of $2bn in a potential sale.

Areas of the healthcare industry will likely be triggered into action, spurring innovation, as bottlenecks in the system become increasingly clear amid covid-19, Adams told PE Hub.

Telehealth tackles the coronavirus and CapVest-backed Curium calls off its potential $3 billion sale.

Barclays and Moelis have been engaged for sell-side financial advice, however the timeline of the process is unclear amid market uncertainty.

As the JPM and Rothschild process for the French nuclear medicine company is put on hold, attention shifts to Webster Equity-backed PharmaLogic, sources told PE Hub.

TSG Consumer makes a big splash in vet care amid other activity in the lower middle market, with L1 Health's Destination Pet buying VitalPet out of bankruptcy following Cortec's recent acquisition of Lap of Love.